Nicolas Barthelemy

Nicolas Barthelemy (senior executive) discloses dealings in 4 companies, chiefly Repligen Corp, Standard Biotools Inc. and Twist Bioscience Corp. In total, 15 filings cover trades dated from 13 May 2021 to 15 May 2025.

The open-market side counts 2 purchases for €378k alongside 1 sale for €199k. On balance, insiders were net buyers of €179k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 7 share grants and 5 option exercises.

The latest filing, published on 21 May 2025, reports a share grant in Repligen Corp. The clock since the last published purchase (14 June 2024) now reads 856 days. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.